Background Qishen(QS) capsules, a Traditional Chinese Medicine, has been widely used to treat coronary heart disease in China. However, evidence of its effectiveness remains unclear. Methods To explore whether QS has ...Background Qishen(QS) capsules, a Traditional Chinese Medicine, has been widely used to treat coronary heart disease in China. However, evidence of its effectiveness remains unclear. Methods To explore whether QS has cardioprotective efficacy and/or promotes angiogenesis after myocardial infarction (MI), we performed experiments in a preclinical rat MI model. One month after left anterior descending coronary artery ligation, the rats received either QS solution (0.4 g/kg/day) or the same volume of saline by intragastric injection for four weeks. Results Echocardiographic and hemodynamic analyses demonstrated relatively preserved cardiac function in MI rats administered QS. Indeed, QS treatment was associated with reduced infarct scar size and heart weight index, and these beneficial effects were responsible for enhancing angiogenesis. Mechanistically, QS treatment increased phosphorylation of protein kinase B (Akt) and downregulated phosphorylation of mitogen-activated protein kinase/extracellular-regulated kinase (MEK/ERK). Conclusions QS therapy can improve the cardiac function of rats after MI by an underlying mechanism involving increased angiogenesis, at least partially via activation of the Akt signaling pathway and inhibition of MEK/ERK phosphorylation.展开更多
Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Coch...Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.展开更多
目的探讨芪参还五胶囊联合丁苯酞对痰瘀互结型早期血管性痴呆患者认知功能的改善作用。方法选取2020年1月—2020年12月期间河北省沧州中西医结合医院治疗的痰瘀互结型早期血管性痴呆患者90例为研究对象,将入选患者按随机数字表法分为西...目的探讨芪参还五胶囊联合丁苯酞对痰瘀互结型早期血管性痴呆患者认知功能的改善作用。方法选取2020年1月—2020年12月期间河北省沧州中西医结合医院治疗的痰瘀互结型早期血管性痴呆患者90例为研究对象,将入选患者按随机数字表法分为西药组44例和中西药联合组46例。西药组给予单纯的丁苯酞软胶囊治疗,中西药联合组在西药组的基础上增加芪参还五胶囊治疗,观察比较两组患者简易精神状态量表(Mini-Mental State Examination,MMSE)评分、血清超敏C反应蛋白(High sensitivity c-reactive protein,hs-CRP)、白细胞介素-6(Interleukin-6,IL-6)、神经元特异性烯醇化酶(Neuron specific enolase,NSE)水平、p38MAPK通路蛋白表达及日常生活能力量表(Activity of daily living scale,ADL)评分。结果治疗后两组患者智能各维度及总分均较治疗前升高,差异有统计学意义(P<0.05);且中西药联合组患者智能各维度及总分明显高于西药组,差异有统计学意义(P<0.05)。治疗后两组患者血清hs-CRP、IL-6、NSE水平均较治疗前明显降低,差异有统计学意义(P<0.05);且中西药联合组明显低于西药组,差异有统计学意义(P<0.05)。治疗后两组患者外周血P-p38MAPK、P-p38MAPK/p38MAPK蛋白表达量较治疗前明显降低,差异有统计学意义(P<0.05);p38MAPK蛋白表达量与治疗前比较,差异无统计学意义(P>0.05);且中西药联合组外周血P-p38MAPK、P-p38MAPK/p38MAPK蛋白表达量低于西药组,差异有统计学意义(P<0.05);p38MAPK蛋白表达量与西药组比较,差异无统计学意义(P>0.05)。治疗后两组患者生活基本技能各分项及总分均较治疗前降低,差异有统计学意义(P<0.05);且中西药联合组患者生活基本技能各分项及总分明显低于西药组,差异有统计学意义(P<0.05)。结论采用芪参还五胶囊联合丁苯酞对早期血管性痴呆患者(痰瘀互结型)进行治疗可以明显改善患者智能和生活基本技能,�展开更多
文摘Background Qishen(QS) capsules, a Traditional Chinese Medicine, has been widely used to treat coronary heart disease in China. However, evidence of its effectiveness remains unclear. Methods To explore whether QS has cardioprotective efficacy and/or promotes angiogenesis after myocardial infarction (MI), we performed experiments in a preclinical rat MI model. One month after left anterior descending coronary artery ligation, the rats received either QS solution (0.4 g/kg/day) or the same volume of saline by intragastric injection for four weeks. Results Echocardiographic and hemodynamic analyses demonstrated relatively preserved cardiac function in MI rats administered QS. Indeed, QS treatment was associated with reduced infarct scar size and heart weight index, and these beneficial effects were responsible for enhancing angiogenesis. Mechanistically, QS treatment increased phosphorylation of protein kinase B (Akt) and downregulated phosphorylation of mitogen-activated protein kinase/extracellular-regulated kinase (MEK/ERK). Conclusions QS therapy can improve the cardiac function of rats after MI by an underlying mechanism involving increased angiogenesis, at least partially via activation of the Akt signaling pathway and inhibition of MEK/ERK phosphorylation.
基金National Natural Science Foundation of China (No.81803925)National Key Research and Development Program (No.2017YFC1700102)。
文摘Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.
文摘目的探讨芪参还五胶囊联合丁苯酞对痰瘀互结型早期血管性痴呆患者认知功能的改善作用。方法选取2020年1月—2020年12月期间河北省沧州中西医结合医院治疗的痰瘀互结型早期血管性痴呆患者90例为研究对象,将入选患者按随机数字表法分为西药组44例和中西药联合组46例。西药组给予单纯的丁苯酞软胶囊治疗,中西药联合组在西药组的基础上增加芪参还五胶囊治疗,观察比较两组患者简易精神状态量表(Mini-Mental State Examination,MMSE)评分、血清超敏C反应蛋白(High sensitivity c-reactive protein,hs-CRP)、白细胞介素-6(Interleukin-6,IL-6)、神经元特异性烯醇化酶(Neuron specific enolase,NSE)水平、p38MAPK通路蛋白表达及日常生活能力量表(Activity of daily living scale,ADL)评分。结果治疗后两组患者智能各维度及总分均较治疗前升高,差异有统计学意义(P<0.05);且中西药联合组患者智能各维度及总分明显高于西药组,差异有统计学意义(P<0.05)。治疗后两组患者血清hs-CRP、IL-6、NSE水平均较治疗前明显降低,差异有统计学意义(P<0.05);且中西药联合组明显低于西药组,差异有统计学意义(P<0.05)。治疗后两组患者外周血P-p38MAPK、P-p38MAPK/p38MAPK蛋白表达量较治疗前明显降低,差异有统计学意义(P<0.05);p38MAPK蛋白表达量与治疗前比较,差异无统计学意义(P>0.05);且中西药联合组外周血P-p38MAPK、P-p38MAPK/p38MAPK蛋白表达量低于西药组,差异有统计学意义(P<0.05);p38MAPK蛋白表达量与西药组比较,差异无统计学意义(P>0.05)。治疗后两组患者生活基本技能各分项及总分均较治疗前降低,差异有统计学意义(P<0.05);且中西药联合组患者生活基本技能各分项及总分明显低于西药组,差异有统计学意义(P<0.05)。结论采用芪参还五胶囊联合丁苯酞对早期血管性痴呆患者(痰瘀互结型)进行治疗可以明显改善患者智能和生活基本技能,�
